Latest News - Psoriasis

Friday, February 16, 2018

Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasis

Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities …

Read the full story

Friday, February 16, 2018

Stelara Reduces Aortic Vascular Inflammation

In addition to its effects on skin inflammation, Stelara (Ustekinumab) reduces aortic inflammation, report researchers from the Perelman School of Medicine at the University of Pennsylvania …

Read the full story

Thursday, February 15, 2018

Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meeting

Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include…

Read the full story

Wednesday, February 14, 2018

FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatment

The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved…

Read the full story

Thursday, February 08, 2018

FDA Approves Cosentyx Label Update to Include Scalp Psoriasis

The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label inc…

Read the full story

Monday, January 15, 2018

Cochrane Review: Biologics Trump Other Systemics for Pso

Biologics appear to be the most effective systemic medicines for achieving a chronic plaque psoriasis score of PASI (Psoriasis Area and Severity Index) 90, according to a newly published Cochrane Revi…

Read the full story

Thursday, December 21, 2017

UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritis

UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy i…

Read the full story

Friday, December 15, 2017

NPF Launches New Resource for Youth with Psoriasis, Psoriatic Arthritis

Our Spot, a new resource launched by The National Psoriasis Foundation (NPF),  provides resources for kids and teens living with psoriasis and psoriatic arthritis. The program includes a web…

Read the full story

Wednesday, December 13, 2017

Study: Minorities Less Likely to See a Doctor for Psoriasis

Minorities are less likely than white Americans to see a doctor for psoriasis treatment despite the fact that their disease may be more severe, a new study shows. Researchers from the Perelman Scho…

Read the full story

Wednesday, November 22, 2017

New Analysis Provides Reassurance on Biosimilar Safety

And they’re … safe. Biosimilars, which have been available in the European Union since 2006, show no substantial differences in the reporting of safety information than their originato…

Read the full story

Friday, November 17, 2017

Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjector

Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional …

Read the full story

Thursday, November 16, 2017

Parent-supplied Photos May Allow Pediatric Derms to Make Virtual Diagnoses

Parent-supplied photos taken via smartphone cameras can allow pediatric dermatologists to make a diagnosis without an office visit in many cases, new research shows. This finding, which appear…

Read the full story

Wednesday, November 15, 2017

Psoriasis Severity Linked to Diabetes Risk

Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researcher…

Read the full story

Tuesday, November 14, 2017

Ortho Dermatologics Announces Aspire Higher Scholarship Honorees

Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or four-y…

Read the full story

Wednesday, November 08, 2017

Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors

Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and sympt…

Read the full story
Load More